On November 22, 2023, Femasys Inc. closed the transaction. The company received $1,850,000 in its second and final tranche. The company received funding pursuant to Regulation D in the transaction from 4 investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.27 USD | -8.63% | +2.83% | +30.26% |
May. 09 | Earnings Flash (FEMY) FEMASYS Reports Q1 Revenue $271,140 | MT |
Apr. 01 | HC Wainwright Adjusts Femasys' Price Target to $12 From $10, Reiterates Buy Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2.177 USD | +0.77% | +0.77% | 18.26M | ||
1.27 USD | -8.63% | +2.83% | 30.72M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.26% | 30.72M | |
-4.91% | 183B | |
+0.46% | 108B | |
-3.62% | 67.51B | |
+3.26% | 50.67B | |
+9.11% | 44.7B | |
+2.41% | 40.95B | |
+6.39% | 26.8B | |
+3.83% | 26.71B | |
+12.66% | 24.62B |
- Stock Market
- Equities
- FEMY Stock
- News Femasys Inc.
- Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors